NEW YORK, Sept. 23, 2020 /PRNewswire/ -- Oppenheimer
& Co. Inc. ("Oppenheimer") – a leading investment bank, wealth
manager, and a subsidiary of Oppenheimer Holdings (NYSE: OPY) –
today announced that it has successfully concluded its virtual Fall
Healthcare Life Sciences & MedTech Summit. The event, held
virtually September 21 – 23, brought
together over 120 leading companies from across the life sciences
and medical technology sectors to discuss critical trends and
opportunities with investors.
Michael Margolis, R.Ph.,
Oppenheimer's Co-Head of Healthcare Investment Banking and Head of
Healthcare Life Sciences Investment Banking, said, "The past three
months has been an extremely active time for life science and Med
Tech companies to raise capital. We were very pleased to offer
companies and investors the opportunity to connect in their
meetings and presentations and to help the industry move
Oppenheimer hosted three keynote sessions from thought leaders
who offered critical insights on significant current issues:
- Joseph Grogan, Assistant
to President Donald J. Trump and
Director of the Domestic Policy Council, and Jen Psaki, Former Senior Advisor to
President Obama and Secretary Kerry, participated in a panel
moderated by Michael Margolis,
titled "Election Scenarios and Implications for Healthcare;"
- Dr. Scott Gottlieb, a
physician who formerly served as Food and Drug Administration
Commissioner (2017-2019); and Senior Advisor for CMS, provided an
update on the current state of Covid-19; and
- Dr. Andrew Lo, Professor
of Finance and Director of the Laboratory for Financial Engineering
at MIT Sloan Management School, spoke on "The Intersection of
Biotech and Finance."
The three-day event featured presentations and fireside chats
from over 100 life sciences and medical technology companies.
Oppenheimer's healthcare Life Science and Med Tech equity research
analysts attended to facilitate discussions and questions for the
- Matt Biegler, Emerging
- Mark Breidenbach, Emerging
- Francois Brisebois,
- Kevin DeGeeter, Biotechnology
- Leland Gershell,
- Suraj Kalia, Medical Technology
- Justin Kim, Biotechnology
- Steven M. Lichtman, Medical
- Jay Olson, CFA,
- Hartaj Singh, Biotechnology
Erica L. Moffett, Managing
Director and Associate Director of Research at Oppenheimer, said,
"This has been an extraordinary year in all respects and we are
pleased to be able to offer virtual conferences for our clients as
they continue to seek insight and investment opportunities in the
Oppenheimer's next conference will be our MedTech Summit on
Oppenheimer & Co. Inc.
Oppenheimer & Co.
Inc. Oppenheimer & Co. Inc. (Oppenheimer), a principal
subsidiary of Oppenheimer Holdings Inc. (OPY on the New York Stock
Exchange), and its affiliates provide a full range of wealth
management, securities brokerage and investment banking services to
high net-worth individuals, families, corporate executives, local
governments, businesses and institutions.
Kuo / Chris Clemens
Haven Tower Group
424 317 4851 or 424 317 4854
firstname.lastname@example.org or email@example.com
SOURCE Oppenheimer & Co. Inc.